PARP Inhibitors and Prostate Cancer: To Infinity and Beyond BRCA

The U.S. Food and Drug Administration recently approved two poly‐adenosine diphosphate‐ribose polymerase (PARP) inhibitors, olaparib and rucaparib, for treatment of biomarker‐positive metastatic castrate resistant prostate cancer. The benefits of PARP inhibition have been well characterized in patie...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Oncologist
Main Authors: Risdon, Emily N., Chau, Cindy H., Price, Douglas K., Sartor, Oliver, Figg, William D.
Format: Artigo
Jezik:Inglês
Izdano: John Wiley & Sons, Inc. 2020
Teme:
Genitourinary Cancer
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7794174/
https://ncbi.nlm.nih.gov/pubmed/32790034
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2020-0697
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki